Tofacitinib was one of the earliest oral JAK-inhibitors to reach the autoimmune-disease market, and it remains a widely prescribed alternative for patients who've exhausted conventional and TNF-inhibitor therapy — its oral tablet format gives it the same logistical simplicity advantage as Baricitinib, making it a straightforward addition for distributors already carrying our injectable Adalimumab and Infliximab lines who want a complete oral option too.
- Approved indications: Rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, ankylosing spondylitis
- Mechanism: Inhibits JAK1 and JAK3 enzymes, interrupting the intracellular signaling cascade that drives chronic inflammation
- Administration: Oral tablet, typically twice daily (immediate-release) or once daily (extended-release formulation)
- Distribution advantage: No cold chain, no infusion infrastructure, no self-injection training required — the simplest supply chain of any immunotherapy product in our catalogue
- Boxed-warning class risk: Same JAK-inhibitor risk profile as Baricitinib — increased risk of serious infection, malignancy, major cardiovascular events, and thrombosis, particularly in patients over 50 with cardiovascular risk factors
- Screening requirement: Active TB and hepatitis screening mandatory before starting
- Contraindication: Pregnancy
- Monitoring: Regular blood counts, lipid panel, and liver function tests recommended throughout treatment
- Certification: WHO-GMP tablet manufacturing
- Batch-specific testing: Dissolution and bioequivalence testing per batch
| Document |
Included |
| Certificate of Analysis (COA) |
? Standard |
| Certificate of Origin (COO) |
? Standard |
| MSDS |
? Standard |
Stock status: Available on request | Quote turnaround: 24 hours
- Logistics: Standard export logistics, no cold chain required
- Coverage: Global export markets
- Cost advantage: Meaningfully lower shipping and handling cost compared to injectable biologics in the same therapeutic category
- Institutional buyers: Pharmacy and hospital distributor support
- Portfolio fit: A natural complementary SKU for distributors already carrying Adalimumab or Infliximab, rounding out a full oral-plus-injectable rheumatology offering
- Unregistered markets: Named-patient supply pathway available
What is Tofacitinib used for?
Treats rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and ankylosing spondylitis.
Get Tofacitinib price from a GMP-compliant Indian supplier — how?
Send strength and destination for a verified quote.
Does it need cold chain shipping?
No, it's an oral tablet stable at room temperature.
Is it safe for older patients?
Requires caution — JAK-inhibitors carry an elevated risk profile in patients over 50 with cardiovascular risk factors.
Who supplies Tofacitinib from India?
WHO-GMP certified tablet manufacturing with full export documentation.
